Press coverage about Delcath Systems (NASDAQ:DCTH) has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Delcath Systems earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical device company an impact score of 45.7400977652133 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Delcath Systems (NASDAQ:DCTH) opened at 0.092 on Wednesday. Delcath Systems has a one year low of $0.02 and a one year high of $4.72. The firm’s market cap is $10.90 million. The stock has a 50 day moving average price of $0.15 and a 200 day moving average price of $0.14.

WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/09/delcath-systems-nasdaqdcth-getting-somewhat-positive-press-coverage-study-finds.html.

Delcath Systems Company Profile

Delcath Systems, Inc is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS).

Insider Buying and Selling by Quarter for Delcath Systems (NASDAQ:DCTH)

Receive News & Ratings for Delcath Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.